A 68-year-old male with known COPD presents to the emergency department with acute worsening of dyspnoea, increased sputum purulence, and cough for 3 days. Spirometry performed during this acute episode shows the pattern marked **A** in the diagram: FEV1/FVC ratio of 0.42 with post-bronchodilator FEV1 of 32% predicted. Which of the following GOLD 2025 severity classifications and corresponding management priority is most appropriate for this patient's current airflow limitation?
A. GOLD 2 (moderate) — initiate oral corticosteroids and antibiotics as part of exacerbation bundle
B. GOLD 4 (very severe) — initiate mechanical ventilation immediately without trial of non-invasive ventilation
C. GOLD 1 (mild) — manage with short-acting bronchodilators alone; discharge with outpatient follow-up
D. GOLD 3 (severe) — initiate oral corticosteroids and antibiotics; assess need for non-invasive ventilation
Explanation
Why GOLD 3 (severe) — initiate oral corticosteroids and antibiotics; assess need for non-invasive ventilation is right
The spirometric pattern marked A shows a post-bronchodilator FEV1 of 32% predicted, which falls within the GOLD 3 (severe) category (FEV1 30–49% predicted) as defined in GOLD 2025 and Harrison's 21e Chapter 286. The fixed FEV1/FVC ratio of 0.42 (well below 0.70) confirms persistent airflow limitation. During an acute exacerbation of COPD (AECOPD) with increased sputum purulence and dyspnoea, this patient meets criteria for moderate-to-severe exacerbation requiring the structured management bundle: systemic corticosteroids (prednisolone 40 mg for 5 days per REDUCE trial), antibiotics (meeting ≥2 of 3 AECOPD criteria: purulent sputum + increased volume + dyspnoea), supplemental oxygen titrated to SpO2 88–92%, and assessment for non-invasive ventilation if respiratory acidosis develops. The worsening obstructive defect with air trapping and dynamic hyperinflation during exacerbation drives the clinical urgency.
Why each distractor is wrong
GOLD 2 (moderate) — initiate oral corticosteroids and antibiotics as part of exacerbation bundle: GOLD 2 is defined as FEV1 50–79% predicted. The patient's FEV1 of 32% predicted is below this range and therefore classified as GOLD 3 (severe), not GOLD 2. Underestimating severity risks inadequate monitoring for respiratory failure.
GOLD 4 (very severe) — initiate mechanical ventilation immediately without trial of non-invasive ventilation: GOLD 4 is defined as FEV1 <30% predicted. Although the patient's FEV1 of 32% is close to this threshold, it does not meet the <30% criterion. Moreover, GOLD 2025 and Harrison's recommend non-invasive ventilation (BiPAP) as first-line for respiratory acidosis before intubation; immediate mechanical ventilation without NIV trial is not standard practice and would be inappropriate escalation.
GOLD 1 (mild) — manage with short-acting bronchodilators alone; discharge with outpatient follow-up: GOLD 1 is defined as FEV1 ≥80% predicted. An FEV1 of 32% predicted is far below this threshold. Additionally, an acute exacerbation with purulent sputum and dyspnoea in a patient with severe airflow limitation requires systemic corticosteroids, antibiotics, and close monitoring—not outpatient management alone.
High-YieldNEET PG
GOLD 2025 severity is defined by post-bronchodilator FEV1 % predicted (GOLD 3: 30–49%), and acute exacerbations in GOLD 3–4 patients require the full bundle: oxygen, SABAs + SAMAs, prednisolone 40 mg × 5 days, antibiotics (if ≥2 AECOPD criteria), and NIV assessment for respiratory acidosis.
